Shanghai, China — Recently, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (referred to as "VitaFlow Liberty^®"), a new generation transcatheter aortic valve implantation (TAVI) product self-developed by MicroPort CardioFlow Medtech Corporation (02160.HK, hereinafter referred to as " MicroPort^® CardioFlow "), has received market approval from the MEDICAL DEVICE AUTHORITY Malaysia (Authorization Number: GD5322224-178777).

Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) recently announced that following Alwide^® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty^® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty^® ") has received marketing approval  from the Saudi Food and Drug Administration (SFDA).

Santiago, Chile – On May 17, 2024, MicroPort^® CardioFlow Medtech Corporation(" MicroPort^® CardioFlow ", 02160.HK ) completed the first implantation with its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^® ) at the Sótero del Río Hospital in Chile. Dr. Martín Valdebenito, the director of cardiology at the hospital, and Dr. Juan Pablo De Brahi, a renowned Argentine cardiologist, performed the procedure and successfully treated a patient with severe aortic valve stenosis, with no conduction blocks or paravalvular leaks occurring and the transvalvular pressure gradient dropped to 4mmHg postoperatively. The patient was discharged within three days after the successful implantation.